194 related articles for article (PubMed ID: 38897821)
21. An introduction to the clinical practice of theranostics in oncology.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
[TBL] [Abstract][Full Text] [Related]
22. Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.
Calatayud DG; Neophytou S; Nicodemou E; Giuffrida SG; Ge H; Pascu SI
Front Chem; 2022; 10():830133. PubMed ID: 35494646
[TBL] [Abstract][Full Text] [Related]
23. Side effects of theragnostic agents currently employed in clinical practice.
Rizzo A; Annunziata S; Salvatori M
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):315-326. PubMed ID: 34881848
[TBL] [Abstract][Full Text] [Related]
24. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M
Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174
[TBL] [Abstract][Full Text] [Related]
25. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology].
Schaefer N; Prior J
Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036
[TBL] [Abstract][Full Text] [Related]
26. Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
Sandhu S; Guo C; Hofman MS
J Nucl Med; 2021 Aug; 62(12):1660-8. PubMed ID: 34385339
[TBL] [Abstract][Full Text] [Related]
27. Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.
Richter S; Steenblock C; Fischer A; Lemm S; Ziegler CG; Bechmann N; Nölting S; Pietzsch J; Ullrich M
Theranostics; 2024; 14(1):17-32. PubMed ID: 38164150
[TBL] [Abstract][Full Text] [Related]
28. Theranostics in oncology: What radiologists want to know.
Ferdinandus J; Fendler WP; Morigi JJ; Fanti S
Eur J Radiol; 2021 Sep; 142():109875. PubMed ID: 34391057
[TBL] [Abstract][Full Text] [Related]
29. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
D'Huyvetter M; Xavier C; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
Expert Opin Drug Deliv; 2014 Dec; 11(12):1939-54. PubMed ID: 25035968
[TBL] [Abstract][Full Text] [Related]
30. Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach.
Filippi L; Urso L; Bianconi F; Palumbo B; Marzola MC; Evangelista L; Schillaci O
Expert Rev Mol Diagn; 2023 Mar; 23(3):243-255. PubMed ID: 36927210
[TBL] [Abstract][Full Text] [Related]
31. Theranostics in India: a Particularly Exquisite Concept or an Experimental Tool.
Choudhury PS; Gupta M
Nucl Med Mol Imaging; 2019 Apr; 53(2):92-95. PubMed ID: 31057679
[TBL] [Abstract][Full Text] [Related]
32. Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders.
Assadi M; Jokar N; Yordanova A; Gholamrezanezhad A; Amini A; Abbasi F; Biersack HJ; Amini A; Nabipour I; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):429-440. PubMed ID: 34053586
[TBL] [Abstract][Full Text] [Related]
33. Highlights lecture EANM 2015: the search for nuclear medicine's superheroes.
Buck A; Decristoforo C
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1910-27. PubMed ID: 27229941
[TBL] [Abstract][Full Text] [Related]
34. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
[TBL] [Abstract][Full Text] [Related]
35. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
36. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
Choudhury P; Gupta M
Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
[TBL] [Abstract][Full Text] [Related]
37. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
38. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.
Barca C; Griessinger CM; Faust A; Depke D; Essler M; Windhorst AD; Devoogdt N; Brindle KM; Schäfers M; Zinnhardt B; Jacobs AH
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056071
[TBL] [Abstract][Full Text] [Related]
39. Targeted radionuclide therapy: an emerging field in solid tumours.
Artigas C; Mileva M; Flamen P; Karfis I
Curr Opin Oncol; 2021 Sep; 33(5):493-499. PubMed ID: 34183491
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
Ruigrok EAM; Verkaik NS; de Blois E; de Ridder C; Stuurman D; Roobol SJ; Van Gent DC; de Jong M; Van Weerden WM; Nonnekens J
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
